NED TALK 2021: Navigating the Increasingly Complex Therapeutic Landscape in Contemporary MM Care

Join us for this interactive live-stream webinar with a panel of oncology nurses to learn about therapeutic options for multiple myeloma treatment, including the most recent data on first-line therapy and recently approved agents for patients with relapsed/refractory disease. This event will offer attendees the opportunity to have their questions answered by the expert panel.

A virtual Nursing Education Day (NED) that includes short webinar presentations and scheduled audience question and answer sessions with panel discussions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Caring for Patients With Newly Diagnosed Multiple Myeloma
  • Options for a Patient With Early Relapse on RVd
  • Integrate Novel Treatment Classes Into Clinical Practice: Selinexor and Melphalan Flufenamide
  • Current Options and Ongoing Clinical Trials with BCMA Targeted Therapies

Faculty

Program Director
Beth Faiman, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Faculty
Donna Catamero, APN

Nurse Practitioner
Mount Sinai Hospital
New York, New York

Faculty
Charise Gleason, MSN, NP-BC, AOCNP

Advanced Practice Provider Chief
Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Emory University
Atlanta, Georgia

Faculty
Tiffany Richards, PharmD

Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of nurses, physicians assistants and other healthcare providers to optimally care for patients with multiple myeloma.

Target Audience
This educational program is intended for nurses and physicians assistants specializing in hematology/oncology involved in care of patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Provide patient-focused education on the available clinical data and new therapeutic options for the individualized treatment of MM
  • Discuss with patients the available data and rationale for using monoclonal antibodies and antibody–drug conjugates, as well as new-generation immunomodulatory agents and proteasome inhibitors for individual patients with MM
  • Evaluate individualized treatment strategies for older patients through consideration of the available clinical data as well as risk assessment, comorbidities, and patient preferences
  • Develop a proactive management plan for adverse events associated with recently approved agents and novel combinations used to treat MM
  • Manage the physical, emotional, and social challenges experienced by patients diagnosed with MM through all stages of their disease

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.